Seqirus to invest £40 million into UK vaccine manufacturing site
Seqirus, the company created in 2015 when Australian biotech CSL Limited (ASX:CSL) acquired Swiss pharma giant Novartis’ (NOVN: VX) influenza vaccine business, has announced a new investment for a UK manufacturing site.
The £40 million ($52 million) project announced on Wednesday means that since the takeover, more than £60 million has been invested in the Liverpool site, which manufactures bulk material for a range of influenza vaccines, including an adjuvanted influenza vaccine designed for older people.
Currently, the bulk material is shipped to Italy where it is filled into vials and syringes by a contract manufacturer. Seqirus has taken the decision to bring this capability in-house, choosing to invest in a new and expanded fill-and-finish facility on the Liverpool site.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze